title: Non-lymphoma hematological malignancies in systemic lupus erythematosus.
abstract: OBJECTIVE
  To describe non-lymphoma hematological malignancies in systemic lupus erythematosus (SLE).
  
  
  METHODS
  A large SLE cohort was linked to cancer registries. We examined the types of non-lymphoma hematological cancers.
  
  
  RESULTS
  In 16,409 patients, 115 hematological cancers [including myelodysplastic syndrome (MDS)] occurred. Among these, 33 were non-lymphoma. Of the 33 non-lymphoma cases, 13 were of lymphoid lineage: multiple myeloma (n = 5), plasmacytoma (n = 3), B cell chronic lymphocytic leukemia (B-CLL; n = 3), precursor cell lymphoblastic leukemia (n = 1) and unspecified lymphoid leukemia (n = 1). The remaining 20 cases were of myeloid lineage: MDS (n = 7), acute myeloid leukemia (AML; n = 7), chronic myeloid leukemia (CML; n = 2) and 4 unspecified leukemias. Most of these malignancies occurred in female Caucasians, except for plasma cell neoplasms (4/5 multiple myeloma and 1/3 plasmacytoma cases occurred in blacks).
  
  
  CONCLUSIONS
  In this large SLE cohort, the most common non-lymphoma hematological malignancies were myeloid types (MDS and AML). This is in contrast to the general population, where lymphoid types are 1.7 times more common than myeloid non-lymphoma hematological malignancies. Most (80%) multiple myeloma cases occurred in blacks; this requires further investigation.
authors.affiliation: Division of Clinical Epidemiology, McGill University Health Centre, Montreal, Que., Canada.
authors.forename: Mary
authors.initials: M
authors.lastname: Lu
authors.forename: Sasha
authors.initials: S
authors.lastname: Bernatsky
authors.forename: Rosalind
authors.initials: R
authors.lastname: Ramsey-Goldman
authors.forename: Michelle
authors.initials: M
authors.lastname: Petri
authors.forename: Susan
authors.initials: S
authors.lastname: Manzi
authors.forename: Murray B
authors.initials: MB
authors.lastname: Urowitz
authors.forename: Dafna
authors.initials: D
authors.lastname: Gladman
authors.forename: Paul R
authors.initials: PR
authors.lastname: Fortin
authors.forename: Ellen M
authors.initials: EM
authors.lastname: Ginzler
authors.forename: Edward
authors.initials: E
authors.lastname: Yelin
authors.forename: Sang-Cheol
authors.initials: SC
authors.lastname: Bae
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Wallace
authors.forename: Soren
authors.initials: S
authors.lastname: Jacobsen
authors.forename: Mary Anne
authors.initials: MA
authors.lastname: Dooley
authors.forename: Christine A
authors.initials: CA
authors.lastname: Peschken
authors.forename: Graciela S
authors.initials: GS
authors.lastname: Alarcón
authors.forename: Ola
authors.initials: O
authors.lastname: Nived
authors.forename: Lena
authors.initials: L
authors.lastname: Gottesman
authors.forename: Lindsey A
authors.initials: LA
authors.lastname: Criswell
authors.forename: Gunnar
authors.initials: G
authors.lastname: Sturfelt
authors.forename: Lene
authors.initials: L
authors.lastname: Dreyer
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Lee
authors.forename: Ann E
authors.initials: AE
authors.lastname: Clarke
mesh_terms: D000328:Adult; D000368:Aged; D015331:Cohort Studies; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications* / Q000175:diagnosis; D006801:Humans; D015994:Incidence; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000175:diagnosis; D008297:Male; D008875:Middle Aged